

29 JUN 1977

HA016

1) ~~Handwritten note~~ → for info  
2) ~~True White~~ → for file

p/2/2.5

Copies to: D W Barrett, ICI US  
P Slade, Product Planning  
T C Frears, Americas Dept  
M S Rose, CTL  
G A Willis, RATLS

Dr H G Franke  
Chevron Chemical Company  
940 Hensley Street  
Richmond  
CA 94804  
USA

AC/SG

2 June 1977

Dear Hans

PARAQUAT USE CLASSIFICATION AND EMETIC FORMULATION

Thank you for your letter of 23 May with the copy of the Brochure submitted to the FIFRA Scientific Advisory Panel of EPA. This is a most useful document and should go a long way to informing EPA of the true facts regarding paraquat use. I look forward in due course to learn the outcome.

I spoke with Nils briefly today about the emetic situation and the need to prepare a brief for FDA on the value in safety terms of a PQ emetic formulation and the reasons why the emetic in this case should not be regarded as a drug. We will go through our file and let you have anything we find on the subject which we think might be helpful in this connection. I confirm sending the following telex in this connection:

"Ref telephone conversation yesterday with Ospenson on emetic. ICI will prepare a case to help you in your submission to FDA. This will include background to worldwide PQ situation and need for emetic formulation and reasons why this should not be regarded as a drug. Will submit this material by facsimile copier to your S.F. office on 9 June".

I also informed Nils that the situation in W Somoa was back on track. In fact the authorities there will now even be helping us to monitor the situation as the new formulation is introduced.

Yours sincerely

A Calderbank